PB-22 has an [[EC50|EC<sub>50</sub>]] of 5.1&nbsp;nM for human CB<sub>1</sub> receptors, and 37&nbsp;nM for human CB<sub>2</sub> receptors.<ref name="ACS 2015">{{Cite journal | doi = 10.1021/acschemneuro.5b00107| title = Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135| journal = ACS Chemical Neuroscience| pages = 150508124201002| year = 2015| last1 = Banister | first1 = S. D. | last2 = Stuart | first2 = J. | last3 = Kevin | first3 = R. C. | last4 = Edington | first4 = A. | last5 = Longworth | first5 = M. | last6 = Wilkinson | first6 = S. M. | last7 = Beinat | first7 = C. | last8 = Buchanan | first8 = A. S. | last9 = Hibbs | first9 = D. E. | last10 = Glass | first10 = M. | last11 = Connor | first11 = M. | last12 = McGregor | first12 = I. S. | last13 = Kassiou | first13 = M. | volume=6| issue = 8 | pmid=25921407}}</ref> PB-22 produces bradycardia and hypothermia in rats at doses of 0.3–3&nbsp;mg/kg, suggesting potent cannabinoid-like activity.<ref name="ACS 2015" /> The magnitude and duration of hypothermia induced in rats by PB-22 was notably greater than [[JWH-018]], [[AM-2201]], [[UR-144]], [[XLR-11]], [[APICA (synthetic cannabinoid drug)|APICA]], or [[STS-135 (drug)|STS-135]], with a reduction of body temperature still observable six hours after dosing.<ref name="ACS 2015" /> One clinical toxicology study found PB-22 to be the cause of seizures in a human and his dog.<ref>{{Cite journal | doi = 10.3109/15563650.2014.925562| pmid = 24905571| title = 'Crazy Monkey' Poisons Man and Dog: Human and canine seizures due to PB-22, a novel synthetic cannabinoid| journal = Clinical Toxicology| volume = 52| issue = 6| pages = 635–8| year = 2014| last1 = Gugelmann | first1 = H.| last2 = Gerona | first2 = R.| last3 = Li | first3 = C.| last4 = Tsutaoka | first4 = B.| last5 = Olson | first5 = K. R.| last6 = Lung | first6 = D.}}</ref>
